rs12976445 variant in the pri‑miR‑125a correlates with a lower level of hsa‑miR‑125a and ERBB2 overexpression in breast cancer patients
- Authors:
- Published online on: November 22, 2012 https://doi.org/10.3892/ol.2012.1040
- Pages: 569-573
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Expression of MIR125A is diminished in breast tumors, however the reason for the hsa‑mir‑125a decrease in the cancer is not known. HER2 is encoded by ERBB2, a target for hsa‑miR‑125a which interacts with the 3'UTR of ERBB2 mRNA. The present study reveals that a polymorphism (rs12976445) within the pri‑miR‑125a sequence correlates with the amount of mature hsa‑miR‑125a in breast tumor samples. miRNA, RNA and DNA were extracted from breast cancer samples obtained from 26 patients. Following immunohistological evaluation of the samples, the ERBB2, PGR and ESR1 mRNA profiles were also analyzed using real‑time PCR. Genomic DNA was sequenced using MIR125A flanking primers. PCR products were analyzed using a BaeGI restriction enzyme specific to the rs12976445 variant. The rs12976445 variant (C/T and C/C) correlated with a lower level of hsa‑miR‑125a in comparison with the T/T variant. The expression of HER2 mRNA was increased in tumors with the rs12976445 variant (C/T and C/C) compared with T/T. We conclude that rs12976445 may be a potential prognostic marker of HER2 expression in breast cancer. Its predictive value on the efficacy of trastuzumab treatment in patients with HER2‑positive breast cancer warrants further study.
